$6.80
1.59% today
Nasdaq, Feb 28, 05:15 pm CET
ISIN
IL0010941198
Symbol
KMDA
Sector
Industry

Kamada Ltd Stock price

$6.91
+0.01 0.14% 1M
+1.25 22.08% 6M
+0.82 13.46% YTD
+0.51 7.97% 1Y
+1.36 24.50% 3Y
+0.99 16.72% 5Y
+2.40 53.22% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.19 2.68%
ISIN
IL0010941198
Symbol
KMDA
Sector
Industry

Key metrics

Market capitalization $397.23m
Enterprise Value $336.39m
P/E (TTM) P/E ratio 25.27
EV/FCF (TTM) EV/FCF 10.64
EV/Sales (TTM) EV/Sales 2.12
P/S ratio (TTM) P/S ratio 2.51
P/B ratio (TTM) P/B ratio 1.56
Revenue growth (TTM) Revenue growth 4.52%
Revenue (TTM) Revenue $158.38m
EBIT (operating result TTM) EBIT $17.76m
Free Cash Flow (TTM) Free Cash Flow $31.63m
Cash position $72.00m
EPS (TTM) EPS $0.27
P/E forward 29.40
P/S forward 2.46
EV/Sales forward 2.09
Short interest 0.03%
Show more

Is Kamada Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Kamada Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Kamada Ltd forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Kamada Ltd forecast:

Buy
100%

Financial data from Kamada Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
158 158
5% 5%
100%
- Direct Costs 91 91
4% 4%
57%
67 67
19% 19%
43%
- Selling and Administrative Expenses 21 21
17% 17%
13%
- Research and Development Expense 16 16
15% 15%
10%
31 31
23% 23%
19%
- Depreciation and Amortization 13 13
3% 3%
8%
EBIT (Operating Income) EBIT 18 18
44% 44%
11%
Net Profit 16 16
155% 155%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Kamada Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kamada Ltd Stock News

Neutral
GlobeNewsWire
2 days ago
REHOVOT, Israel, and HOBOKEN, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd.
Neutral
GlobeNewsWire
about one month ago
REHOVOT, Israel and HOBOKEN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it was awarded a contract with an international organization for the supply of KAMRAB® and VARIZI...
Neutral
Seeking Alpha
4 months ago
Call Start: 08:30 January 1, 0000 9:52 AM ET Kamada Ltd. (NASDAQ:KMDA ) Q3 2024 Earnings Conference Call November 13, 2024, 08:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Greetings, and welcome to the Kamada Ltd.
More Kamada Ltd News

Company Profile

Kamada Ltd. engages in the development and production of pharmaceutical products. It operates through the Proprietary Products segment and the Distribution segment. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the supply of plasma-based products for clinical use. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.

Head office Israel
CEO Amir London
Employees 378
Founded 1990
Website www.kamada.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today